BSE filing, NSE: AMARDEE. Summary written from the filing by ALFA Finder's alert engine.
Amerise Biosciences Ltd: key numbers
- Share price
- ₹0.79
- Market cap
- ₹5.22 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹0.02 Cr
- P/E (TTM)
- -98.9×Sector 27.1×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Amerise Biosciences Ltd
All →Amerise Biosciences Board Meeting Date
Amerise Biosciences will hold a board meeting on 30 October 2026 to consider Q2 and H1 FY27 unaudited results. This is an advance notice of a future meeting with no financial figures disclosed.
Amerise Biosciences Other Announcement
Amerise Biosciences Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulatory requirements.
Amerise Biosciences Annual General Meeting
Amerise Biosciences Limited conducted its 41st Annual General Meeting on September 24, 2026. Shareholders approved financial statements and the appointment of a new Wholetime Director and CFO.
Amerise Biosciences Annual Report
Amerise Biosciences has submitted its Annual Report for the financial year 2024-25. The company scheduled its 41st Annual General Meeting for September 24, 2026.
Amerise Biosciences Annual General Meeting
Amerise Biosciences Ltd has submitted the notice for its 41st Annual General Meeting, scheduled to be held on September 24, 2026.
Amerise Biosciences Capital Structure Change
Snehjeev Ventures Private Limited and PACs acquired 76,725 equity shares of Amerise Biosciences Ltd. The acquisition increases their aggregate stake from 10.92% to 11.04%.
Other capital structure change announcements
All →Medplus Health Services Capital Structure Change
ICICI Prudential Mutual Fund disclosed under Regulation 29(2) that it bought 24,35,693 Medplus shares, lifting its stake to 9.21%. The acquisition was made in the open market, not off-market.
- Promoter stake change
- +1.97%
Delhivery Capital Structure Change
Delhivery will infuse up to Rs.36 Crore into its wholly owned subsidiary DFDPL in tranches. The funds support the subsidiary's fintech distribution business for logistics participants.
- Value
- ₹36.00 Cr
- Execution
- In one or more tranches, as per DFDPL's business requirement, up to Rs.36 Crore.
Man Infraconstruction Capital Structure Change
Man Infraconstruction bought back 67,000 equity shares on October 30, 2026 at an average price of Rs.106.93. Total buyback so far is 1,04,17,000 shares.
- Value
- ₹0.72 Cr
Blue Chip Tex Industries Capital Structure Change
Blue Chip Tex Industries approved a tender-offer buy-back of 2,50,000 equity shares at Rs.130 per share, up to Rs.3.25 Crore. The record date is set for November 25 to December 2, 2026.
- Value
- ₹3.25 Cr
- Execution
- Record/book closure 25-11-2026 to 02-12-2026; AGM/EGM/postal ballot date 02-12-2026
PB Fintech Capital Structure Change
HDFC Mutual Fund schemes raised their PB Fintech stake by 2.02% to 7.03% via open-market purchases. The acquisition was dated 28 October 2026.
Paras Healthcare Capital Structure Change
360 ONE funds disclose conversion of 78.82 lakh pre-IPO unlisted Paras Healthcare shares into listed shares at 7.28% stake. No new shares were acquired; the holding remained unchanged post-listing.